Abstract
Lysosomes play a key role in regulating cell death in response to cancer therapies, yet little is known on the possible role of lysosomes in the therapeutic efficacy of G-quadruplex DNA ligands (G4L) in cancer cells. Here, we investigate the relationship between the modulation of lysosomal membrane damage and the degree to which cancer cells respond to the cytotoxic effects of G-quadruplex ligands belonging to the triarylpyridine family. Our results reveal that the lead compound of this family, 20A promotes the enlargement of the lysosome compartment as well as the induction of lysosome-relevant mRNAs. Interestingly, the combination of 20A and chloroquine (an inhibitor of lysosomal functions) led to a significant induction of lysosomal membrane permeabilization coupled to massive cell death. Similar effects were observed when chloroquine was added to three new triarylpyridine derivatives. Our findings thus uncover the lysosomal effects of triarylpyridines compounds and delineate a rationale for combining these compounds with chloroquine to increase their anticancer effects.
Highlights
Lysosomes are the end points of several vesicular pathways that mediate degradation of intra- and extra-cellular material in cells [1]
We have previously shown that 20A, a G-quadruplex ligand belonging to the triarylpyridine family, exerts potent cytotoxic and cytostatic effects on several cancer cells
Our study uncovers the lysosomal effects of G4 ligands belonging to the triarylpyridine family and proposes a rationale for combining these compounds with chloroquine to increase their effectiveness against cancer
Summary
Lysosomes are the end points of several vesicular pathways that mediate degradation of intra- and extra-cellular material in cells [1]. Lysosomes ensure the regulation of numerous biological processes including nutrient sensing, signaling to the nucleus, and the ignition of cell death pathways [2]. Mounting evidence indicates that lysosomes are involved in the resistance to anticancer compounds with weak base properties. These drugs may be sequestered within the lysosome, resulting in a loss of accessibility of the drug to its cellular targets and thereby a reduction of its effectiveness [7,8,9,10]. Inhibition of lysosomal sequestration (by increasing lysosomal pH, or inhibiting active transport) may increase the sensitivity of cancer cells to several antineoplastic therapies [13]. The modifications of the lysosomal compartment that occur during cellular transformation can paradoxically render cancer cells more susceptible to lysosomal membrane permeabilization (LMP) [14,15], and lead to lysosomal-dependent cell death (LDCD) induced by anticancer agents [13,16]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
